Crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid calcium salt (2:1)

US6605729B1 · kind B1 · utility

Assignee

• WARNER-LAMBERT COMPANY LLC · US

Inventors

• Stephen R. Byrn · West Lafayette, US
• David Coates · Bishop's Stortford, GB
• Karen S. Gushurst · Lafayette, US
• Joseph Francis Krzyzaniak · Pawcatuck, US
• Zheng Li · Quaker Hill, US
• Henry Morrison · Dublin, US
• Aeri Park · West Lafayette, US
• Petinka Vlahova · West Lafayette, US

Key dates

• Filing date: Jun 28, 2002
• Grant date: Aug 12, 2003
• Expiry date: Jun 28, 2022

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D207/34
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Novel crystalline forms of [R-(R*,R*)]-2-(4-fluorophenyl)-&bgr;,&dgr;-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt designated Form V, Form VI, Form VII, Form VIII, Form IX, Form X, Form XI, Form XII, Form XIII, Form XIV, Form XV, Form XVI, Form XVII, Form XVIII, and Form XIX are characterized by their X-ray powder diffraction, solid-state NMR, and/or Raman spectroscopy are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, and Alzheimer's disease.